Transcriptional E2F1/2/5/8 as potential targets and transcriptional E2F3/6/7 as new biomarkers for the prognosis of human lung carcinoma.

Transcriptional E2F1/2/5/8 as potential targets and transcriptional E2F3/6/7 as new biomarkers for the prognosis of human lung carcinoma.
复制标题

DOI:
10.18632/aging.101441
复制
发表时间:
2018-05-11
期刊:
Aging
影响因子:
--
通讯作者:
Li DJ
Li DJ
中科院分区:
其他
文献类型:
--
作者:
Sun CC;Zhou Q;Hu W;Li SJ;Zhang F;Chen ZL;Li G;Bi ZY;Bi YY;Gong FY;Bo T;Yuan ZP;Hu WD;Zhan BT;Zhang Q;Tang QZ;Li DJ

文献摘要

参考文献

被引文献

相似文献

E2F是高等真核生物中编码转录因子家族的一组基因,在哺乳动物细胞中参与细胞周期调控和DNA合成。来自细胞系、小鼠模型和人体组织的证据表明,tf与肺癌(LC)肿瘤发生有关。然而,8种e2f的不同表达模式和预后价值尚未阐明。在目前的研究中,我们检查了来自ONCOMINE、GEPIA、Kaplan-Meier Plotter和cBioPortal数据库的LC患者中E2Fs的转录和生存数据。我们发现E2F1/2/3/5/6/7/8在肺腺癌和鳞状细胞肺癌组织中的表达水平高于肺组织,而E2F4在肺腺癌和鳞状细胞肺癌中的表达水平低于肺组织。E2F2/4/5/7/8的表达水平与肿瘤分期有关。Kaplan-Meier Plotter数据库的生存分析显示,在所有LC患者中,高转录水平的E2F1/2/4/5/7/8与低无复发生存(RFS)相关。相反,高E2F3/6水平预示着这些患者的高RFS。本研究提示E2F3/6/7是LC患者精准治疗的潜在靶点,E2F1/2/4/5/8是预测LC预后的新生物标志物。
E2F is a group of genes that encode a family of transcription factors (TFs) in higher eukaryotes and participate in cell cycle regulation and DNA synthesis in mammalian cells. Evidence from cell lines, mouse models, and human tissues indicates that TFs are implicated in lung cancer (LC) tumorigenesis. However, the diverse expression patterns and prognostic values of eight E2Fs have yet to be elucidated. In the current study, we examined the transcriptional and survival data of E2Fs in patients with LC from ONCOMINE, GEPIA, Kaplan–Meier Plotter, and cBioPortal databases. We found that the expression levels of E2F1/2/3/5/6/7/8 were higher in lung adenocarcinoma and squamous cell lung carcinoma tissues than in lung tissues, whereas the expression level of E2F4 was lower in the former than in the latter. The expression levels of E2F2/4/5/7/8 were correlated with advanced tumor stage. Survival analysis using the Kaplan–Meier Plotter database revealed that the high transcription levels of E2F1/2/4/5/7/8 were associated with low relapse-free survival (RFS) in all of the patients with LC. Conversely, high E2F3/6 levels predicted high RFS in these patients. This study implied that E2F3/6/7 are potential targets of precision therapy for patients with LC and that E2F1/2/4/5/8 are new biomarkers for the prognosis of LC.
DOI: 10.3233/cbm-160196
发表时间: 2017-01-01
期刊: CANCER BIOMARKERS
影响因子: 3.1
作者:
Al Ahmed, Hala Abdel;Nada, Ola
通讯作者: Nada, Ola
DOI: 10.1002/path.1121
发表时间: 2002-10-01
影响因子: 7.3
作者:
Gorgoulis, VG;Zacharatos, P;Papavassiliou, AG
通讯作者: Papavassiliou, AG
DOI: 10.1158/0008-5472.can-09-3082
发表时间: 2010-01-15
期刊: CANCER RESEARCH
影响因子: 11.2
作者:
Deng, Qing;Wang, Qun;Han, Ze-Guang
通讯作者: Han, Ze-Guang
小细胞肺癌中受转录因子 E2F1 调控的靶基因
DOI: 10.13294/j.aps.2016.0043
发表时间: 2016-06-25
期刊: Shengli Xuebao
影响因子: --
作者:
Li Zun-Ling;Jiao Fei;Kong Li-Jun
通讯作者: Kong Li-Jun
DOI: 10.1016/j.bbrc.2016.08.030
发表时间: 2016-09-16
影响因子: 3.1
作者:
Fang, Jing;Sun, Cheng-Cao;Gong, Cheng
通讯作者: Gong, Cheng